We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? (Bismuth-PBH)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00892502
First Posted: May 4, 2009
Last Update Posted: September 10, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Copenhagen University Hospital at Herlev
  Purpose
The purpose of this study is to determine whether treatment with Bismuth can reduce the toxicity of chemotherapy and radiotherapy in patients with malignant diseases of the blood.

Condition Intervention
Hematological Diseases Hematological Malignancies Blood Diseases Malignant Lymphoma Leukemia Multiple Myeloma Drug: Bismuth tablets Drug: Placebo tablets

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? A Clinical, Prospective, Randomized, Blinded Examination of Patients Suffering From Hematological Malignancies Treated With Intensive Chemotherapy and/or Radiotherapy.

Resource links provided by NLM:


Further study details as provided by Copenhagen University Hospital at Herlev:

Primary Outcome Measures:
  • To evaluate a possible protective effect of bismuth on the mucous membranes during chemotherapy and radiotherapy [ Time Frame: daily during treatment ]

Secondary Outcome Measures:
  • To identify the effect of bismuth on the regulation of metallothionein in tumour tissue and healthy tissue, respectively [ Time Frame: 6 months ]

Enrollment: 50
Study Start Date: May 2009
Study Completion Date: February 2013
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Bismuth tablets
Drug: Bismuth tablets
1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
Placebo Comparator: 2
Placebo tablets, containing no active substance
Drug: Placebo tablets
1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients of 18 years or over referred to the Department of Haematology L, Herlev Hospital, with a view to 'cytostatic'? treatment of or radiotherapy for haematological malignancy

Exclusion Criteria:

  • Pregnant women and nursing mothers
  • No informed consent from patient
  • Known hyper sensitivity to bismuth or other tablet content
  • Severe renal insufficiency with creatinin clearance below 25 ml/min.
  • Patients receiving other treatment for protection of the mucous membrane except cryo treatment of the oral cavity (lumps of ice in the mouth)
  • Other experimental treatment within past four weeks.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00892502


Locations
Denmark
Department of Haematology L, Herlev Hospital, Herlev Ringvej 75
Herlev, Denmark, DK-2650
Sponsors and Collaborators
Copenhagen University Hospital at Herlev
Investigators
Principal Investigator: Per B Hansen, MD Department of Haematology, Copenhagen University Hospital at Herlev
  More Information

Responsible Party: Copenhagen University Hospital at Herlev
ClinicalTrials.gov Identifier: NCT00892502     History of Changes
Other Study ID Numbers: 2007-007652-34
First Submitted: May 1, 2009
First Posted: May 4, 2009
Last Update Posted: September 10, 2013
Last Verified: September 2013

Keywords provided by Copenhagen University Hospital at Herlev:
haematology
haematological
hematology
hematological
malignancy
lymphoma
myeloma
leukemia
blood diseases
malignant
bismuth

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms
Lymphoma
Hematologic Diseases
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Lymphatic Diseases
Bismuth
Antacids
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents